Sofwave Medical Reports First Quarter 2024 Financial Results and Business Highlights
SAN CLEMENTE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2024, for the period ended March 31, 2024, and recent business highlights.
- First quarter revenue of $13.2M, +27% year-over-year growth; IFRS gross margin of 75.2%
First quarter pulse recurring revenue of $4.7M, +118% year-over-year growth
IFRS and non-IFRS operating loss narrowed to -$1.0M and -$0.4M, respectively; company approaching breakeven
SAN CLEMENTE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2024, for the period ended March 31, 2024, and recent business highlights. - First Quarter Revenue of $13.2M; representing 27% year-over-year growth
IFRS Operating Loss: $1.0M; down from $3.7 million in first quarter of 2023; *Non-IFRS Operating Loss: $0.4M
Cash and Cash Equivalents as of March 31, 2024: $23.1M, Cash used in the first quarter of 2024 of $1.3M down from $3.0M in the first quarter of 2023. - Mr. Louis Scafuri, Sofwave CEO, commented, “We continue to experience significant tailwinds for our disruptive technology and unique business model, as demonstrated by the 27% top-line growth generated in the first quarter of 2024.
- Of significance, recurring pulse sales are an increasingly significant contributor to our strong financial results, with recurring pulse sales representing more than one third of our total first quarter revenue.